Xopenex

Bronchial Spasm, prophylaxis of Bronchospasm, Chronic Obstructive Pulmonary Disease
Treatment
3 FDA approvals
20 Active Studies for Xopenex

What is Xopenex

LevosalbutamolThe Generic name of this drug
Treatment SummaryLevosalbutamol (levalbuterol) is a medication used to treat asthma and COPD. It is a form of salbutamol, which is a drug that works by stimulating a specific type of receptor in the body. Levosalbutamol is an enantiomerically pure (R)-salbutamol formulation, meaning it is only made up of the one beneficial form of salbutamol, rather than a mixture of two forms. It is used to reduce the risk of potential side effects from the other form of salbutamol.
Xopenexis the brand name
image of different drug pills on a surface
Xopenex Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Xopenex
Levosalbutamol
1999
79

Approved as Treatment by the FDA

Levosalbutamol, commonly known as Xopenex, is approved by the FDA for 3 uses which include Bronchospasm and Bronchial Spasm .
Bronchospasm
Bronchial Spasm
prophylaxis of Bronchospasm

Effectiveness

How Xopenex Affects PatientsThis drug helps to open the airways in the lungs, making it easier to breathe. This can provide relief for shortness of breath.
How Xopenex works in the bodyLevosalbutamol works by activating beta-2 adrenergic receptors on the airway smooth muscle. When these receptors are activated, a chain of events is set off that leads to the relaxing of the muscle and a decrease in inflammation. This helps to reduce the intensity of asthma attacks.

When to interrupt dosage

The recommended dosage of Xopenex is contingent upon the diagnosed condition, including Chronic Obstructive Pulmonary Disease (COPD), Bronchospasm and prevention of Bronchospasm. The amount of dosage is contingent upon the delivery approach (e.g. Respiratory (inhalation) or Oral) detailed in the table below.
Condition
Dosage
Administration
Bronchial Spasm
, 0.045 mg, 12.5 mg/mL, 1.25 mg/mL, 0.63 mg/mL, 0.31 mg/mL
Oral, Aerosol, metered - Oral, Aerosol, metered, , Respiratory (inhalation), Solution, concentrate, Solution, concentrate - Respiratory (inhalation), Solution, Solution - Respiratory (inhalation)
prophylaxis of Bronchospasm
, 0.045 mg, 12.5 mg/mL, 1.25 mg/mL, 0.63 mg/mL, 0.31 mg/mL
Oral, Aerosol, metered - Oral, Aerosol, metered, , Respiratory (inhalation), Solution, concentrate, Solution, concentrate - Respiratory (inhalation), Solution, Solution - Respiratory (inhalation)
Chronic Obstructive Pulmonary Disease
, 0.045 mg, 12.5 mg/mL, 1.25 mg/mL, 0.63 mg/mL, 0.31 mg/mL
Oral, Aerosol, metered - Oral, Aerosol, metered, , Respiratory (inhalation), Solution, concentrate, Solution, concentrate - Respiratory (inhalation), Solution, Solution - Respiratory (inhalation)

Warnings

Xopenex has one contraindication and should not be concomitantly employed with the conditions in the following table.Xopenex Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
There are 20 known major drug interactions with Xopenex.
Common Xopenex Drug Interactions
Drug Name
Risk Level
Description
2,5-Dimethoxy-4-ethylthioamphetamine
Minor
The risk or severity of hypertension can be increased when Levosalbutamol is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
5-methoxy-N,N-dimethyltryptamine
Minor
The risk or severity of hypertension can be increased when Levosalbutamol is combined with 5-methoxy-N,N-dimethyltryptamine.
Acemetacin
Minor
The risk or severity of hypertension can be increased when Levosalbutamol is combined with Acemetacin.
Albutrepenonacog alfa
Minor
Levosalbutamol may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Alclofenac
Minor
The risk or severity of hypertension can be increased when Levosalbutamol is combined with Alclofenac.
image of a doctor in a lab doing drug, clinical research

Xopenex Novel Uses: Which Conditions Have a Clinical Trial Featuring Xopenex?

98 active clinical trials are presently being conducted to explore the potential of Xopenex in providing prophylaxis of Bronchospasm, Chronic Obstructive Pulmonary Disease (COPD) and Bronchospasm relief.
Condition
Clinical Trials
Trial Phases
prophylaxis of Bronchospasm
0 Actively Recruiting
Chronic Obstructive Pulmonary Disease
77 Actively Recruiting
Phase 3, Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 4
Bronchial Spasm
0 Actively Recruiting

Xopenex Reviews: What are patients saying about Xopenex?

5Patient Review
11/20/2011
Xopenex for Bronchospasm Prevention
I've had asthma for 30 years and have found that you need to mix up your medication. For example, albuterol can become ineffective if used too much. Xopenex solution works great if you use it selectively, such as when you have a cold or lung infection.
5Patient Review
8/24/2010
Xopenex for Bronchospasm Prevention
This medication has helped my child a lot. They've been struggling with asthma attacks and this offers some much-needed relief that other medications haven't been able to provide.
5Patient Review
11/15/2010
Xopenex for Asthma Attack
This cough syrup was incredibly effective. Within 15 to 20 minutes, my coughing fits were totally under control.
4.7Patient Review
5/4/2010
Xopenex for Bronchospasm Prevention
My daughter was given this medication for RSV, but shortly after using it she developed small ulcers on her tongue. The more we used it, the worse they got. She's in a lot of pain and has lost 5lbs in less than a week. I've stopped the treatments and she sounds better, but if anyone has had this experience please let me know what to do to help her!
4.7Patient Review
12/29/2010
Xopenex for Bronchospasm Prevention
We've been really pleased with the results of this medication for my son's asthma. His allergy specialist put him on it a few years ago and it's made such a difference.
4.3Patient Review
11/20/2012
Xopenex for Asthma Attack
Xopenex is a great alternative to Pro-Air if you're looking for something that won't make your heart race. It's also more affordable, which is an added bonus.
4Patient Review
1/19/2010
Xopenex for Asthma Attack
2.7Patient Review
1/13/2010
Xopenex for Asthma Attack
2.3Patient Review
12/17/2010
Xopenex for Bronchospasm
I developed worse breathing problems after a couple months of using this medication, so I stopped. It's not worth it to me to continue use if it's going to make my condition worse.
2.3Patient Review
2/27/2012
Xopenex for Asthma Attack
Though easy to use, this unfortunately didn't work for me and I ended up in the hospital with an asthma attack.
1.7Patient Review
12/16/2017
Xopenex for Asthma Attack
The effects of this treatment were very short-lived, only about thirty minutes. Not worth the money or time in my opinion.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about xopenex

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is xopenex the same as albuterol?

"Albuterol and Xopenex are both drugs that are used to treat similar conditions. They are both available as inhalants, and generic versions of both are now available. The cost of both drugs is roughly the same."

Answered by AI

Is Xopenex inhaler a steroid?

"Xopenex (levalbuterol) is a bronchodilator, which means it relaxes the muscles in your lungs. Some people also use steroids to help manage their asthma. These two types of medications work well together to help you breathe, but they are not the same thing."

Answered by AI

Why would xopenex be ordered instead of albuterol?

"Levalbuterol, sold under the brand name Xopenex among others, is a medication used to treat bronchospasm for people with asthma or COPD. It is one of a group of medicines called beta agonists. Unlike other beta agonists, levalbuterol's effect on heart rate is less. It is available as a generic medication. The nebulizer solution is a good option for children and adults who have difficulty using a handheld inhaler."

Answered by AI

What is xopenex used for?

"Levalbuterol is used to quickly treat wheezing and shortness of breath that commonly occur with lung problems, such as asthma and chronic obstructive pulmonary disease. Controlling these symptoms can decrease time lost from work or school."

Answered by AI

Clinical Trials for Xopenex

Image of Stanford University in Stanford, United States.

MoblO2 for Chronic Lung Diseases

18+
All Sexes
Stanford, CA
Many patients with chronic lung disease (e.g., chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD)) require supplemental oxygen (O2) at some point during their disease course. Practitioners prescribe O2 to patients with chronic lung disease in hopes of the following: 1) that it will limit desaturation events and combat breathlessness, thus preventing the frustratingly slow pace and numerous rest breaks patients are forced to adopt while doing even simple tasks; 2) that it will allow patients to be more active physically (perhaps increase their ability to exercise) and socially (perhaps leave the home more often); 3) that it will stave off putative complications of hypoxemia (e.g., cognitive dysfunction, pulmonary hypertension) and 4) that it will improve health-related quality of life (HRQL). However, despite the rationale for O2, and prescribers' good intentions, patients generally view O2 with frustration and fear - it threatens their HRQL, which is already impaired by having a condition that imposes itself on every aspect of their lives. Nasal cannulas and delivery devices call unwanted attention to patients when they are out in public. O2 users feel stigmatized and are often viewed as "smokers who get what they deserve, even if they never smoked a day in their lives" - or as disabled, sick or even infectious. O2 steals patients' independence, forcing them to plan their lives around it. The anxiety that patients and their caregivers experience around running out of oxygen, or not getting enough, immobilizes them and restricts participation in activities outside of the home. O2 disrupts the home environment, adding stress, and creating a burden for patients' caregiver-loved-ones who are often saddled with the responsibility of ensuring adequate equipment and supply of O2, and O2 is a constant reminder to patients they are living with a condition that could shorten their lives. O2 delivery equipment is typically heavy, unwieldy and intimidating. Different recommendations (e.g., insurance companies use 88% as a cut-off for SpO2, while many practitioners focus on 90%) make it confusing for patients, which almost certainly affects adherence. O2-requiringpatients are starving for things that can make their lives easier. An auto-adjusting O2 delivery device - one that automatically delivers the correct amount of O2 to maintain blood oxygen at desired, pre-set levels - would alleviate the need for patients to constantly (incessantly for many) monitor their peripheral oxygen saturation (SpO2) and adjust O2flow to meet the demands as exertion levels vary . The MoblO2 device is a battery-operated, light-weight, closed-loop O2 delivery device that houses a regulator (which attaches to compressed gas O2 tanks) and adjusts O2 flow to meet a pre-set blood oxygen level. A pulse oximeter is worn on the ear and transmits via Bluetooth to the device, which adjusts an internal valve to control flow on a second-to-second basis. The user sets the dial to the highest flow of O2 needed to meet the demands of activities they might perform (up to 15 liters per minute), and the device adjusts flow, up to the pre-set level to maintain SpO2 at a preset level (e.g., \> 90%). To conserve O2 supply in the tank - and to avoid over-oxygenation (which could be problematic for a small percentage of patients with the most severe COPD) - the MoblO2 begins to limit O2 flow at a SpO2 of 93%. The device can be manually over-ridden by the user, and should the battery run out - or the device fail for some unforeseen reason - the default position is valve open, so the users receive whatever flow of oxygen has been set on the dial. Given the substantial burdens of O2 on patients and their families, the hassles patients describe with having to monitor their SpO2 and repeatedly adjust the flow of O2 to meet their needs, patients and experts around the world have called for improvements in O2 delivery equipment. The MoblO2 is just such a remarkable improvement and a giant step forward in helping to ease the burdens of O2 on patients who require it. The purpose of this study is to investigate the effects of the MoblO2 O2 delivery device on a range of outcomes, including physical activity, amount (liters) O2 use; maintenance of adequate SpO2 levels; patient reported outcomes including symptoms, HRQL and satisfaction with the MoblO2 O2 device.
Waitlist Available
Has No Placebo
Stanford UniversityJeff Swigris, DO, MSMinnesota Health Solutions
Have you considered Xopenex clinical trials? We made a collection of clinical trials featuring Xopenex, we think they might fit your search criteria.Go to Trials
Image of The University of Tennessee Graduate School of Medicine in Knoxville, United States.

Nebulizer vs Inhaler for COPD

18+
All Sexes
Knoxville, TN
The purpose of this study is to compare the effectiveness of inhaled bronchodilators delivered via nebulizers vs. dry powder inhalers (DPIs) in symptomatic participants with Chronic Obstructive Pulmonary Disease (COPD) who have airflow obstruction (FEV1/FVC ≤ 70%) and show significant air trapping (RV ≥ 120% of predicted). The investigators hypothesize that, in patients with symptomatic COPD, therapy with a long-acting anti muscarinic agent/long-acting beta agonist (LAMA/LABA) combination administered by nebulizer will improve hyperinflation (increase in inspiratory capacity and reduction in residual volume) and reduce symptoms related to COPD to a greater extent than LAMA/LABA therapy given by a DPI. The study aims to demonstrate the following: 1. Compare the values of inspiratory capacity (IC) and residual volume (RV) in patients receiving LAMA/LABA by DPI with those receiving LAMA/LABA by nebulizer 2. Compare patient reported outcomes (COPD Assessment Test (CAT score), Baseline/Transition Dyspnea Index (BDI/TDI) and the St. George Respiratory Questionnaire (SGRQ) in symptomatic patients with COPD receiving LAMA/LABA by DPI with those receiving LAMA/LABA by nebulizer
Phase 4
Recruiting
The University of Tennessee Graduate School of MedicineTheravance Biopharma
Have you considered Xopenex clinical trials? We made a collection of clinical trials featuring Xopenex, we think they might fit your search criteria.Go to Trials
Image of University of Massachusetts Chan Medical School in Worcester, United States.

Paramedic Evaluation for Chronic Obstructive Pulmonary Disease

18+
All Sexes
Worcester, MA
Chronic Obstructive Pulmonary Disease (COPD) is a serious lung condition that affects millions of people in the United States. Each year, it leads to about 150,000 deaths, nearly 900,000 emergency room visits, and 700,000 hospital stays. When COPD symptoms suddenly get worse-called an exacerbation-it can seriously harm a person's quality of life and often requires emergency care. Treating these flare-ups early can help prevent hospital visits, but right now, there aren't many good ways to make sure people get care quickly. Mobile Integrated Health (MIH) programs send specially trained paramedics, guided remotely by doctors, to care for patients in their homes. This approach could help people with COPD get faster, more effective care without needing to go to the hospital. In this project, the investigators are testing a new program called PEACE (Paramedic Evaluation for Acute COPD Exacerbation). The PEACE program sends community paramedics to patients' homes-when needed and in partnership with their regular doctors-to manage worsening COPD symptoms early. The study team will adapt the PEACE program to meet the needs of adults living at home with moderate to severe COPD, gather feedback from patients and healthcare providers, and run a small pilot study to see if the program is practical and helpful.
Recruiting
Has No Placebo
University of Massachusetts Chan Medical SchoolLaurel O'Connor, MD, MSc
Image of Cleveland Clinic Foundation in Cleveland, United States.

Multidisciplinary Clinic Evaluation for Sarcopenia Due to COPD

18+
All Sexes
Cleveland, OH
Sarcopenia, or skeletal muscle loss, impacts up to 40% of COPD patients and is a major cause for morbidity and mortality. Despite the high clinical significance of sarcopenia in COPD, the diagnosis remains elusive because accurate measures of skeletal muscle are not tested during routine clinical care. The goal is to use evidence-based strategies to diagnose and treat sarcopenia due to COPD. The multidisciplinary team includes a pulmonologist, pharmacist, COPD nurse, and COPD coordinator. The investigators anticipate that the approach will improve clinical outcomes for COPD patients with sarcopenia as compared to standard of care visits in ambulatory COPD clinics. The investigators will determine if the approach improves skeletal muscle mass and function, and also improves clinical outcomes related to frequency of hospitalization or ED (Emergency Department) visits, COPD exacerbations, and mortality.
Recruiting
Has No Placebo
Cleveland Clinic FoundationAmy Attaway, MD
Image of Duke Asthma Allergy and Airway Center in Durham, United States.

Inhaled Treprostinil for Chronic Obstructive Pulmonary Disease

18+
All Sexes
Durham, NC
The goal of this clinical trial is to evaluate whether inhaled Treprostinil (Tyvaso) can improve oxygen delivery and blood flow in the lungs in adults (age ≥40) with chronic obstructive pulmonary disease (COPD) and hypoxemia who have less severe reduction in lung blood volume (diffusing capacity of the lungs for carbon monoxide \[DLCO\] ≥45%). The main questions it aims to answer are: 1. Does inhaled Treprostinil increase pulmonary capillary blood volume in ventilated lung regions, as measured by hyperpolarized xenon-129 magnetic resonance imaging (HP129Xe MRI)? 2. Does inhaled Treprostinil improve oxygen delivery (measured as red blood cell \[RBC\] chemical shift) and maintain or only slightly change pulmonary vascular resistance (measured by RBC oscillation amplitude)? 3. Can pre-treatment MRI parameters (RBC transfer and RBC oscillation amplitude) predict who will respond to inhaled Treprostinil? Participants will: * Use the Tyvaso nebulizer (inhaled Treprostinil) 4 times daily for 4 weeks, starting at 3 breaths per session and increasing to a maximum of 6 breaths per session as tolerated. * Undergo HP129Xe MRI before and after treatment to assess regional lung function and oxygen exchange. * Complete pulmonary function tests (PFTs), 6-minute walk tests (6MWT), and echocardiograms at the beginning and end of the study. * Be monitored for adverse events, with a phone check-in midway through and after the treatment period.
Phase 2
Recruiting
Duke Asthma Allergy and Airway CenterUnited Therapeutics
Have you considered Xopenex clinical trials? We made a collection of clinical trials featuring Xopenex, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security